Network topology determines dynamics of the mammalian MAPK1,2 signaling network: Bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R

FASEB Journal

Volumn 22, Issue 5, 2008, Pages 1393-1403

  Muller, Melissa ^a   Obeyesekere, Mandri ^a   Mills, Gordon B ^a   Ram, Prahlad T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Computational modeling; Melanoma; Proteomics

Indexed keywords

B RAF KINASE; C RAF PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR; INTERMEDIN; MELANOCYTE STIMULATING HORMONE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; RAF PROTEIN;

ARTICLE; DYNAMICS; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; MAMMAL; MELANOMA CELL; MOLECULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

AMINO ACID MOTIFS; CELL LINE, TUMOR; COMPUTER SIMULATION; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTOR, MELANOCORTIN, TYPE 1; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 43249109885     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-9100com     Document Type: Article

References (55)

1. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037
2. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A. E., Capdeville, R., Druker, B. J., and the IRIS Investigators (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004
3. Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D., and Joensuu, H. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480
4. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792
5. Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Jr., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., Swain, S. M., Pisansky, T. M., Fehrenbacher, L., Kutteh, L. A., Vogel, V. G., Visscher, D. W., Yothers, G., Jenkins, R. B., Brown, A. M., Dakhil, S. R., Mamounas, E. P., Lingle, W. L., Klein, P. M., Ingle, J. N., and Wolmark, N. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N. Engl. J. Med. 353, 1673-1684
6. Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C. H., Steger, G., Huang, C.-S., Andersson, M., Inbar, M., Lichinitser, M., Lang, I., Nitz, U., Iwata, H., Thomssen, C., Lohrisch, C., Suter, T. M., Ruschoff, J., Suto, T., Greatorex, V., Ward, C., Straehle, C., McFadden, E., Dolci, M. S., Gelber, R. D., and the Herceptin Adjuvant (HERA) Trial Study Team (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672
7. Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., Li, J. Z., Bello, C. L., Theuer, C. P., George, D. J., and Rini, B. I. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24
8. Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., Rowinsky, E., Abbruzzese, J. L., Xia, C., Simantov, R., Schwartz, B., and O'Dwyer, P. J. (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512
9. Dumaz, N., Hayward, R., Martin, J., Ogilvie, L., Hedley, D., Curtin, J. A., Bastian, B. C., Springer, C., and Marais, R. (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRaf to CRaf and disrupted cyclic AMP signaling. Cancer Res. 66, 9483-9491
10. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. (2002) Mutations of the BRaf gene in human cancer. Nature 417, 949-954
11. Goydos, J. S., Mann, B., Kim, H. J., Gabriel, E. M., Alsina, J., Germino, F. J., Shih, W., and Gorski, D. H. (2005) Detection of B-RAF and N-RAS mutations in human melanoma. J. Am. Coll. Surg. 200, 362-370
12. Goel, V. K., Lazar, A. J., Warneke, C. L., Redston, M. S., and Haluska, F. G. (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 126, 154-160
13. Tsao, H., Goel, V., Wu, H., Yang, G., and Haluska, F. G. (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122, 337-341
14. Tsao, H., Zhang, X., Fowlkes, K., and Haluska, F. G. (2000) Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 60, 1800-1804
15. Strumberg, D. (2005) Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc.) 41, 773-784
16. Ahmad, T., Marais, R., Pyle, L., James, B., Schwartz, B., Gore, M., and Eisen, T. (2004) BAY 43-9006 in patients with advanced melanoma: the Royal Marsden experience. J. Clin. Oncol. 22(14S), 7506
17. Lorusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., Hanson, L., DeLuca, P., Bruzek, L., Piens, J., Asbury, P., Van Becelaere, K., Herrera, R., Sebolt-Leopold, J., and Meyer, M. B. (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 23, 5281-5293
18. Ma'ayan, A., Jenkins, S. L., Neves, S., Hasseldine, A., Grace, E., Dubin-Thaler, B., Eungdamrong, N. J., Weng, G., Ram, P. T., Rice, J. J., Kershenbaum, A., Stolovitzky, G. A., Blitzer, R. D., and Iyengar, R. (2005) Formation of regulatory patterns during signal propagation in a Mammalian cellular network. Science 309, 1078-1083
19. Bhalla, U. S., and Iyengar, R. (1999) Emergent properties of networks of biological signaling pathways. Science 283, 381-387
20. Bhalla, U. S., Ram, P. T., and Iyengar, R. (2002) MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 297, 1018-1023
21. Kashtan, N., and Alon, U. (2005) Spontaneous evolution of modularity and network motifs. Proc. Natl. Acad. Sci. U. S. A. 102, 13773-13778
22. Garrington, T. P., and Johnson, G. L. (1999) Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. 11, 211-218
23. Vossler, M. R., Yao, H., York, R. D., Pan, M. G., Rim, C. S., and Stork, P. J. (1997) cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89, 73-82
24. Busca, R., Abbe, P., Mantoux, F., Aberdam, E., Peyssonnaux, C., Eychene, A., Ortonne, J. P., and Ballotti, R. (2000) Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J. 19, 2900-2910
25. Cook, S. J., and McCormick, F. (1993) Inhibition by cAMP of Ras-depenndent activation of Raf. Science 262, 1069-1072
26. Wu, J., Dent, P., Jelinek, T., Wolfman, A., Weberr, M. J., and Sturgill, T. W. (1883) Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3-,5--monophosphae. Science 262, 1065-1069
27. Dumaz, N., and Marais, R. (2005) Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J. 272, 3491-3504
28. Dumaz, N., and Marais, R. (2003) Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J. Biol. Chem. 278, 29819-29823
29. Brummer, T., Naegele, H., Reth, M., and Misawa, Y. (2003) Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 22, 8823-8834
30. Dougherty, M. K., Muller, J., Ritt, D. A., Zhou, M., Zhou, X. Z., Copeland, T. D., Conrads, T. P., Veenstra, T. D., Lu, K. P., and Morrison, D. K. (2005) Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215-224
31. Balan, V., Leicht, D. T., Zhu, J., Balan, K., Kaplun, A., Singh-Gupta, V., Qin, J., Ruan, H., Comb, M. J., and Tzivion, G. (2006) Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol. Biol. Cell 17, 1141-1153
32. Jacobowitz, O., and Iyengar, R. (1994) Phorbol ester-induced stimulation and phosphorylation of adenylyl cyclase 2. Proc. Natl. Acad. Sci. U. S. A. 91, 10630-10634
33. Murphy, L. O., Smith, S., Chen, R. H., Fingar, D. C., and Blenis, J. (2002) Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4, 556-564
34. Cook, S. J., and McCormick, F. (1996) Kinetic and biochemical correlation between sustained p44ERK1 (44 kDa extracellular signal-regulated kinase 1) activation and lysophosphatidic acid-stimulated DNA synthesis in Rat-1 cells. Biochem. J. 320(Pt 1), 237-245
35. Hoffman, A., Levchenko, A., Scott, M. L., and Baltimore, D. (2002) The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 298, 1241-1245
36. Marshall, C. J. (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185
37. Kholodenko, B. N. (2007) Untangling the signalling wires. Nat. Cell Biol. 9, 247-249
38. Chin, L. (2003) The genetics of malignant melanoma: lessons from mouse and man. Nat. Rev. Cancer 3, 559-570
39. Miller, A. J., and Mihm, M. C., Jr. (2006) Melanoma. N. Engl. J. Med. 355, 51-65
40. Nesbit, M., Nesbit, H. K., Bennett, J., Andl, T., Hsu, M. Y., Dejesus, E., McBrian, M., Gupta, A. R., Eck, S. L., and Herlyn, M. (1999) Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 18, 6469-6476
41. Slominski, A., Tobin, D. J., Shibahara, S., and Wortsman, J. (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 84, 1155-1228
42. Landi, M. T., Bauer, J., Pfeiffer, R. M., Elder, D. E., Hulley, B., Minghetti, P., Calista, D., Kanetsky, P. A., Pinkel, D., and Bastian, B. C. (2006) MC1R germline variants confer risk for BRAF-mutant melanoma. Science 313, 521-522
43. Bhalla, U. S. (2002) Mechanisms for temporal tuning and filtering by postsynaptic signaling pathways. Biophys. J. 83, 740-752
44. Gao, L., Feng, Y., Bowers, R., Becker-Hapak, M., Gardner, J., Council, L., Linette, G., Zhao, H., and Cornelius, L. A. (2006) Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res. 66, 7880-7888
45. Alon, U. (2003) Biological networks: the tinkerer as an engineer. Science 301, 1866-1867
46. Hornberg, J. J., Tijssen, M. R., and Lankelma, J. (2004) Synergistic activation of signalling to extracellular signal-regulated kinases 1 and 2 by epidermal growth factor and 4 beta-phorbol 12-myristate 13-acetate. Eur. J. Biochem. 271, 3905-3913
47. Garnett, M. J., Rana, S., Paterson, H., Barford, D., and Marais, R. (2005) Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963-969
48. Wan, P. T., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Jones, C. M., Marshall, C. J., Springer, C. J., Barford, D., and Marais, R. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867
49. Yamaguchi, T., Wallace, D. P., Magenheimer, B. S., Hempson, S. J., Grantham, J. J., and Calvet, J. P. (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J. Biol. Chem. 279, 40419-40430
50. Sidovar, M. F., Kozlowski, P., Lee, J. W., Collins, M. A., He, Y., and Graves, L. M. (2000) Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase. J. Biol. Chem. 275, 28688-28694
51. Santos, S. D., Verveer, P. J., and Bastiaens, P. I. (2007) Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat. Cell Biol. 9, 324-330
52. Sasagawa, S., Ozaki, Y., Fujita, K., and Kuroda, S. (2005) Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nat. Cell Biol. 7, 365-373
53. Robubi, A., Mueller, T., Fueller, J., Hekman, M., Rapp, U. R., and Dandekar, T. (2005) B-Raf and C-Raf signaling investigated in a simplified model of the mitogenic kinase cascade. Biol. Chem. 386, 1165-1171
54. Satyamoorthy, K., Li, G., Gerrero, M. R., Brose, M. S., Volpe, P., Weber, B. L., Van Belle, P., Elder, D. E., and Herlyn, M. (2003) Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 63, 756-759
55. Sun, S. Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., and Khuri, F. R. (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052-7058